Clostridioides difficile

Patent metadata

Field	Value
Publication number	US-12397045-B2
Application number	US-201917046700-A
Country	US
Kind code	B2
Filing date	Apr 11, 2019
Priority date	Apr 13, 2018
Publication date	Aug 26, 2025
Grant date	Aug 26, 2025

Abstract

The invention relates to Clostridioides difficile, and in particular to compounds, polypeptides and mixtures for the treatment of C. difficile infections. The invention also relates to nucleic acids, vectors comprising these nucleic acids and microorganisms for the treatment of C. difficile infections, and to methods of identifying and matching faecal microbiota transplant (FMT) donors to FMT recipients.

First claim

The invention claimed is:

1. A method of treating, preventing or ameliorating a Clostridioides difficile infection by selectively inhibiting the growth of Clostridioides difficile , the method comprising administering, to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I):

wherein R 1 is a C 4 to C 6 alkyl or fluorinated alkyl; and
R 2 is hydrogen or a C 1 to C 4 alkyl or halogenated alkyl, and the C 1 to C 4 alkyl or halogenated alkyl is optionally substituted with between 1 and 5 substituents, wherein each substituent has the formula:

wherein each R 3 is independently a C 2 to C 10 alkyl or halogenated alkyl;
or a pharmaceutically acceptable salt of the compound of Formula I, solvate of the compound of Formula I, tautomeric form of the compound of Formula I or polymorphic form of the compound of Formula I.

2. The method according to claim 1 , wherein the compound is of the Formula (Ia):

wherein R 1 is a C 4 to C 6 alkyl or fluorinated alkyl; and
R 2 is hydrogen or a C 1 to C 4 alkyl or halogenated alkyl;
or a pharmaceutically acceptable salt of the compound Formula (Ia), solvate of the compound Formula (Ia), tautomeric form of the compound Formula (Ia) or polymorphic form of the compound Formula (Ia).

3. The method according to claim 1 , wherein R 2 is hydrogen.

4. The method according to claim 1 , wherein R 1 is a C 4 alkyl or fluorinated alkyl.

5. The method according to claim 1 , wherein R 1 is butyl.

6. The method according to claim 1 , wherein R 1 is pentyl or a fluorinated pentyl.

7. The method according to claim 1 , wherein R 1 is hexyl or a fluorinated hexyl.

Assignees

• Imperial College Sci Tech & Medicine

Inventors

• Marchesi Julian
• Mcdonald Julie
• Mullish Benjamin

Classifications

• C12Y305/01024

  Choloylglycine hydrolase (3.5.1.24), i.e. bile salt hydrolase · CPC title

• C12Q1/34

  involving hydrolase · CPC title

• A61K31/215

  of carboxylic acids · CPC title

• A61K31/19

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title